• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Glaukos Corporation (Amendment)

    2/14/23 4:10:18 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care
    Get the next $GKOS alert in real time by email
    SC 13G/A 1 tm236668d1_sc13ga.htm SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13G

    (Amendment No. 7)*

     

    Under the Securities Exchange Act of 1934

     

    GLAUKOS CORPORATION

    (Name of Issuer)

     

    Common Stock

    (Title of Class of Securities)

     

    377322102

    (CUSIP Number)

     

    December 31, 2022

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ¨Rule 13d-1(b)
    ¨Rule 13d-1(c)
    xRule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     

     

    CUSIP No. 377322102

     

    SCHEDULE 13G Page 2 of 5 Pages

     

    1

    NAMES OF REPORTING PERSONS

     

    Thomas W. Burns

    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a)      ¨

    (b)      ¨

    3

    SEC USE ONLY

     

     

    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    USA

     

     

    NUMBER OF

     

    SHARES

     

    BENEFICIALLY

     

    OWNED BY

     

    EACH

     

    REPORTING

     

    PERSON WITH 

    5

    SOLE VOTING POWER

     

    2,707,641(1)

     

    6

    SHARED VOTING POWER

     

    100,000(2)

     

    7

    SOLE DISPOSITIVE POWER

     

    2,707,641(1)

     

    8

    SHARED DISPOSITIVE POWER

     

    100,000(2)

     

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    2,807,641

     

    10

    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES           ¨

     

    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    5.71%(3)

     

    12

    TYPE OF REPORTING PERSON

     

    IN

     

       

    (1)Includes (i) 1,378,261 shares issuable upon the exercise of options that are currently exercisable or will vest and become exercisable, and shares that will be delivered upon the vesting of restricted stock units, within 60 days of December 31, 2022, (ii) 593,426 shares held by Mr. Burns, (iii) 238,107 shares held by the Burns Annuity Trust as of December 31, 2022, of which Mr. Burns is a beneficiary and co-Trustee, (iii) 120,000 shares held by the Burns Charitable Remainder Trust as of December 31, 2022, of which Mr. Burns is a beneficiary and co-Trustee, (iv) 277,847 shares held by the Burns Family Trust as of December 31, 2022, of which Mr. Burns is a beneficiary and co-Trustee and (v) 100,000 shares held by the Thomas W. Burns Irrevocable Trust as of December 31, 2022, of which Mr. Burns is a beneficiary.

     

    (2)Represents 100,000 shares held by the Janet M. Burns Irrevocable Trust as of December 31, 2022, of which Mr. Burns is trustee and Mr. Burns’ spouse is a beneficiary.

     

    (3)Based upon 47,754,475 shares of Glaukos Corporation common stock outstanding at December 31, 2022.

     

     

     

     

    CUSIP No. 377322102

     

    SCHEDULE 13G Page 3 of 5 Pages

     

    Item 1(a)

    Name of Issuer:

     

    Glaukos Corporation (“Issuer”)

     

    Item 1(b)Address of Issuer’s Principal Executive Offices:

     

    1 Glaukos Way, Aliso Viejo, CA 92656

     

    Item 2(a)Name of Person Filing:

     

    Thomas W. Burns

     

    Item 2(b)Address of Principal Business Office or, If None, Residence

     

    Same as Item 1(b)

     

    Item 2(c)Citizenship

     

    See Row 4 of cover page

     

    Item 2(d)

    Title of Class of Securities:

     

    Common stock, $0.001 par value per share

     

    Item 2(e)CUSIP Number:

    377322102

     

    Item 3.

    Statement Filed Pursuant to Rule 13d-1(b) or 13d-2(b) or (c):

     

    Not applicable.

     

    Item 4.Ownership

     

    (a)Amount Beneficially Owned: See Row 9 of cover page.

     

    (b)Percent of Class. See Row 11 of cover page.

     

    (c)Number of shares as to which the person has:

     

    i.Sole power to vote or to direct the vote: See Row 5 of cover page.

     

    ii.Shared power to vote or to direct the vote: See Row 6 of cover page.

     

    iii.Sole power to dispose of or to direct the disposition of: See Row 7 of cover page.

     

    iv.Shared power to dispose or to direct the disposition of: See Row 8 of cover page.

     

    Item 5.

    Ownership of Five Percent or Less of a Class

     

    Not applicable.

     

    Item 6.

    Ownership of More than Five Percent on Behalf of Another Person

     

    Not applicable.

     

     

     

     

    CUSIP No. 377322102

     

    SCHEDULE 13G Page 4 of 5 Pages

     

    Item 7.Identification and Classification of Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person

     

    Not applicable.

     

    Item 8.Identification and Classification of Members of the Group

     

    Not applicable.

     

    Item 9.Notice of Dissolution of Group

     

    Not applicable.

     

    Item 10.Certifications

     

    Not applicable.

     

     

     

      

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2023

     

      Thomas W. Burns
     
      /s/ Thomas W. Burns

     

     

     

    Get the next $GKOS alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $GKOS

    DatePrice TargetRatingAnalyst
    5/1/2025$86.00Overweight → Equal Weight
    Wells Fargo
    2/19/2025$140.00 → $200.00Neutral → Outperform
    Mizuho
    12/11/2024$132.00 → $162.00Neutral → Buy
    Citigroup
    12/6/2024$182.00Buy
    UBS
    12/2/2024$120.00Equal-Weight → Underweight
    Morgan Stanley
    7/10/2024$132.00Buy → Neutral
    Citigroup
    5/6/2024$84.00 → $125.00Hold → Buy
    Jefferies
    12/21/2023$66.00 → $91.00Neutral → Overweight
    JP Morgan
    More analyst ratings

    $GKOS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for IDOSE TR issued to GLAUKOS CORP

    Submission status for GLAUKOS CORP's drug IDOSE TR (ORIG-1) with active ingredient TRAVOPROST has changed to 'Approval' on 12/13/2023. Application Category: NDA, Application Number: 218010, Application Classification: Type 3 - New Dosage Form

    12/15/23 11:41:09 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    FDA Approval for TRAVOPROST issued to GLAUKOS CORP

    Submission status for GLAUKOS CORP's drug TRAVOPROST (ORIG-1) with active ingredient TRAVOPROST has changed to 'Approval' on 12/13/2023. Application Category: NDA, Application Number: 218010, Application Classification: Type 3 - New Dosage Form

    12/14/23 7:41:03 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    $GKOS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Glaukos downgraded by Wells Fargo with a new price target

    Wells Fargo downgraded Glaukos from Overweight to Equal Weight and set a new price target of $86.00

    5/1/25 7:44:23 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Glaukos upgraded by Mizuho with a new price target

    Mizuho upgraded Glaukos from Neutral to Outperform and set a new price target of $200.00 from $140.00 previously

    2/19/25 7:02:55 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Glaukos upgraded by Citigroup with a new price target

    Citigroup upgraded Glaukos from Neutral to Buy and set a new price target of $162.00 from $132.00 previously

    12/11/24 7:52:08 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    $GKOS
    SEC Filings

    View All

    SEC Form S-8 filed by Glaukos Corporation

    S-8 - GLAUKOS Corp (0001192448) (Filer)

    8/20/25 4:15:43 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    SEC Form SCHEDULE 13G filed by Glaukos Corporation

    SCHEDULE 13G - GLAUKOS Corp (0001192448) (Subject)

    8/12/25 10:34:25 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Glaukos Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - GLAUKOS Corp (0001192448) (Filer)

    8/12/25 7:00:14 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    $GKOS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Glaukos Announces Participation in Wells Fargo Healthcare Conference

    Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to participate in the Wells Fargo Healthcare Conference on Wednesday, September 3, 2025, at 10:15 a.m. ET in Boston, MA. A live and archived webcast for these events, where applicable, will be available in the Investors section of the Glaukos website at http://investors.glaukos.com. About Glaukos Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the

    8/13/25 7:00:00 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Glaukos Announces Second Quarter 2025 Financial Results

    Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2025. Key highlights include: Record net sales of $124.1 million in Q2 2025 increased 30% year-over-year on a reported basis and 29% year-over-year on a constant currency basis. Glaucoma record net sales of $103.5 million in Q2 2025 increased 36% year-over-year. U.S. Glaucoma record net sales of $72.3 million in Q2 2025 increased 45% year-over-year. Gross margin of approximately 78% and non-GAAP gross margin of approxima

    7/30/25 4:05:00 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30

    Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2025 financial results after the market close on Wednesday, July 30, 2025. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on July 30, 2025. A link to the live webcast will be available on the company's website at http://investors.glaukos.com. To participate in the conference call, please dial 800-715-9871 (U.S.) or 646-307-1963 (In

    7/9/25 7:00:00 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    $GKOS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Hoffmeister David F exercised 25,000 shares at a strike of $32.00, increasing direct ownership by 361% to 31,918 units (SEC Form 4)

    4 - GLAUKOS Corp (0001192448) (Issuer)

    6/13/25 7:43:41 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Director Foley Mark J was granted 2,972 shares, increasing direct ownership by 64% to 57,221 units (SEC Form 4)

    4 - GLAUKOS Corp (0001192448) (Issuer)

    6/2/25 4:44:12 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Director Hoffmeister David F was granted 2,665 shares, increasing direct ownership by 63% to 6,918 units (SEC Form 4)

    4 - GLAUKOS Corp (0001192448) (Issuer)

    6/2/25 4:43:25 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    $GKOS
    Financials

    Live finance-specific insights

    View All

    Glaukos Announces Second Quarter 2025 Financial Results

    Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the second quarter ended June 30, 2025. Key highlights include: Record net sales of $124.1 million in Q2 2025 increased 30% year-over-year on a reported basis and 29% year-over-year on a constant currency basis. Glaucoma record net sales of $103.5 million in Q2 2025 increased 36% year-over-year. U.S. Glaucoma record net sales of $72.3 million in Q2 2025 increased 45% year-over-year. Gross margin of approximately 78% and non-GAAP gross margin of approxima

    7/30/25 4:05:00 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Glaukos to Release Second Quarter 2025 Financial Results after Market Close on July 30

    Conference Call and Webcast Scheduled for 1:30 p.m. PT Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, plans to release second quarter 2025 financial results after the market close on Wednesday, July 30, 2025. The company's management will discuss the results during a conference call and simultaneous webcast at 1:30 p.m. PT (4:30 p.m. ET) on July 30, 2025. A link to the live webcast will be available on the company's website at http://investors.glaukos.com. To participate in the conference call, please dial 800-715-9871 (U.S.) or 646-307-1963 (In

    7/9/25 7:00:00 AM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Glaukos Announces First Quarter 2025 Financial Results

    Glaukos Corporation (NYSE:GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced financial results for the first quarter ended March 31, 2025. Key highlights include: Record net sales of $106.7 million in Q1 2025 increased 25% year-over-year on a reported basis and 26% year-over-year on a constant currency basis. Glaucoma record net sales of $88.1 million in Q1 2025 increased 31% year-over-year. U.S. Glaucoma record net sales of $59.1 million in Q1 2025 increased 41% year-over-year. Gross margin of approximately 77% and non-GAAP gross margin of approximately

    4/30/25 4:05:00 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    $GKOS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Glaukos Corporation

    SC 13G/A - GLAUKOS Corp (0001192448) (Subject)

    11/14/24 1:21:45 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Glaukos Corporation (Amendment)

    SC 13G/A - GLAUKOS Corp (0001192448) (Subject)

    2/14/24 3:55:55 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by Glaukos Corporation (Amendment)

    SC 13G/A - GLAUKOS Corp (0001192448) (Subject)

    2/13/24 5:41:34 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    $GKOS
    Leadership Updates

    Live Leadership Updates

    View All

    OnCusp Therapeutics Announces Appointment of Robert Forrester and Chau Khuong to Board of Directors

    NEW YORK, Jan. 4, 2023 /PRNewswire/ -- OnCusp Therapeutics, a global biotechnology company with deep translational and clinical development expertise in oncology therapeutics, today announced the appointment of serial entrepreneur Robert Forrester and venture capitalist Chau Khuong as independent board directors. "We are delighted to have Robert and Chau, two seasoned leaders with a wealth of insights and expertise, to join OnCusp's Board. Both are highly regarded and deeply connected in the biotech and investment community," said Dr. Bing Yuan, Chairman and CEO of OnCusp. "Each of these individuals brings unique skill sets to our Board and will be instrumental to advancing OnCusp through se

    1/4/23 8:00:00 AM ET
    $BLU
    $GKOS
    $INSP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical/Dental Instruments
    Biotechnology: In Vitro & In Vivo Diagnostic Substances

    Glaukos Announces Retirement of William J. Link, Ph.D., as Chairman of the Board and Election of Thomas W. Burns as New Chairman and Mark J. Foley as Lead Independent Director

    Glaukos Corporation (NYSE:GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that William J. Link, Ph.D., will be retiring as Chairman of the Board, effective December 31, 2021. Dr. Link joined Glaukos' Board and has served as Chairman since June 2001. In connection with Dr. Link's retirement, the Board has appointed Thomas W. Burns, Glaukos' President and Chief Executive Officer and a director on the Board since 2002, to serve as the company's Chairman of the Board, effective upon Dr. Link's retirement on December 31, 2021. Mr. Burns will continue to serve as th

    12/20/21 4:15:00 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care

    Glaukos Appoints Denice Torres and Dr. Leana Wen to its Board of Directors

    SAN CLEMENTE, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced the appointment of Denice Torres and Dr. Leana Wen to its Board of Directors, effective today. With the addition of these two directors, Glaukos’ Board of Directors will be comprised of nine directors, eight of whom are independent. “We are delighted and honored to welcome these highly accomplished professionals to the Glaukos Board. Each of these extraordinary women brings a wealth of relevant experience, perspective, leadership and wis

    3/1/21 4:10:00 PM ET
    $GKOS
    Medical/Dental Instruments
    Health Care